REIC gene therapy (Momotaro-Gene)

N/A

Report date: 2023/10/26 16:03:01

Base Information

Drug NameREIC gene therapy (Momotaro-Gene)
Drug Alias NameDKK3 gene therapy (Momotaro-Gene)REIC基因治疗重组人REIC/Dkk-3基因复制缺陷5型腺病毒注射液REIC/Dkk-3 gene therapyMTG-201 +[6] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionDickkopf-related protein 3 stimulantsApoptosis stimulantsGene transference
TargetsDickkopf-related protein 3
Therapy Area/IndicationsProstatic NeoplasmsMesothelioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMomotaro-Gene Inc
China Registration ClassN/A

Develop Information

Active CompaniesKyorin Holdings IncOkayama University Tsushima CampusMomotaro-Gene Inc
Inactive CompaniesN/A
Active IndicationsMesothelioma
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A